Welcome to HotCopper’s latest Watchlist, where we’ve been joined by AFT Pharmaceuticals (ASX:AFP) founder and chief executive Hartley Atkinson to talk about the company’s strong sales growth in recent months, all the ongoing R&D initiatives, and a boost in licensing income, as well as the outlook for FY27.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Speaking to HotCopper in Week 21, Mr Atkinson declared, “It’s all been very positive [and] we’ve been getting double-digit growth everywhere.”
Everywhere, in this case, includes every region at home and abroad, including the U.K., North America, and South Africa, where AFT Pharma reported that international sales were up nearly 80% through the financial year.
“We really hope to see this all continue, too, in the process,” Mr Atkinson said.
You can watch the full AFP Watchlist interview in the browser above.
Join the discussion: See what HotCopper users are saying about AFT Pharmaceuticals Ltd and be part of the conversations that move the markets.
Disclaimer: This article is disseminated in partnership with AFT Pharma Ltd. It is intended to inform investors and should not be taken as financial advice.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.